Cargando…
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
Dipeptidyl peptidase-4 inhibitors (DPP-4is) have gained a key place in the management of type 2 diabetes mellitus (T2DM) essentially because of their good safety profile even in the frail population. DPP-4, originally known as ‘T-cell antigen CD26’, is expressed in many immune cells and regulates th...
Autor principal: | Scheen, André J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690941/ https://www.ncbi.nlm.nih.gov/pubmed/33249199 http://dx.doi.org/10.1016/j.diabet.2020.11.005 |
Ejemplares similares
-
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018) -
Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020) -
DPP‐4 inhibition and islet function
por: Ahrén, Bo
Publicado: (2011) -
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
por: Sebastián-Martín, Alba, et al.
Publicado: (2022) -
Is DPP4 inhibition a comrade or adversary in COVID-19 infection
por: Dalan, Rinkoo
Publicado: (2020)